Paediatric and Adolescent Lymphoid Malignancies
Clinical research in lymphoblastic lymphoma and mature aggressive B-cell lymphoma in children and adolescents, with attention to event-free survival, central nervous system relapse, and treatment adaptation in high-risk disease.
- Rituximab-based therapy
- Intensified chemotherapy
- Immune reconstitution
Work in this area also includes strategies for limited and advanced B-cell non-Hodgkin lymphoma, combining antibody-based treatment with standard paediatric oncology regimens.
Diffuse Large B-Cell Lymphoma
Studies in newly diagnosed diffuse large B-cell lymphoma focus on integrating targeted therapy with established R-CHOP-based treatment, with emphasis on progression-free survival and treatment tolerability in adults with intermediate to high International Prognostic Index risk.
- Anti-lymphoma immunotherapy
- Chemotherapy combinations
- Treatment-related safety
The clinical interest extends to B-cell lymphoma management where targeted agents are evaluated alongside conventional immunochemotherapy.
Radioimmunotherapy in High-Grade Glioma
Research activity includes glioblastoma and other surgically treated high-grade glioma settings, with a focus on local treatment approaches after tumour resection and subsequent adjuvant therapy.
- Radioimmunotherapy
- Tumour resection cavity treatment
- Neuro-oncology
This area reflects interest in locoregional strategies for residual or stable tumour burden in aggressive central nervous system tumours.
Multicentre Cooperative Oncology Networks
The sponsor is engaged in internationally coordinated studies across paediatric haematology-oncology and adult lymphoma, linking treatment centres in multiple countries to address rare and complex cancers.
- International trial collaboration
- Paediatric oncology protocols
- Haematological cancer care
These collaborations support research in lymphoma, leukaemia, and brain tumours within coordinated clinical networks.
